Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli. | Ocular Therapeutix is making sure its corporate vision ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

Chinese researchers have suggested that drinking the beverage may lead to a seven-fold higher risk of deteriorated or blurred ...

The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

Toll-like receptors, or TLRs, are the immune system’s early warning sensors. They detect microbial invaders and damage ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.